Discovery of Selective PDE1 Inhibitors Alleviating Pulmonary Fibrosis by the Regulation of TGF-β/Smads and MAPK Pathways
- 22 August 2025
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (17) , 18423-18435
Abstract
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal lung disease with limited treatment options. Our preliminary research identified phosphodiesterase 1 (PDE1) as a potential therapeutic target for IPF treatment. However, both the molecular recognition mechanism between PDE1 inhibitors and the protein, as well as the antifibrotic mechanism, remain incompletely understood. In this study, structural modifications were carried out on a pan-PDE inhibitor 1 we previously developed. The lead compound 4b exhibited an IC50 of 5 nM against PDE1, excellent selectivity across PDE subfamilies and favorable safety properties. Structure-activity relationship analysis combined with binding mode predictions demonstrated that targeting differential residues in the H-loop regions of PDEs is critical for improving selectivity over other PDEs. Furthermore, we demonstrated that the PDE1 inhibitor attenuated pulmonary fibrosis by suppressing both the TGF-β/Smad and MAPK pathways.Keywords
Funding Information
- Natural Science Foundation of Hainan Province (324MS018, KJRC2023B10)
- Hainan University (KYQD(ZR)-21031, KYQD(ZR)-23003, XTCX2022JKA01)
- National Natural Science Foundation of China (22307031, 22370192, 22377023)
This publication has 29 references indexed in Scilit:
- Discovery of Selective PDE1 Inhibitors with Anti-pulmonary Fibrosis Effects by Targeting the Metal PocketJournal of Medicinal Chemistry, 2024
- Discovery of highly potent phosphodiesterase-1 inhibitors by a combined-structure free energy perturbation approachActa Pharmaceutica Sinica B, 2024
- Structural Modifications of Nimodipine Lead to Novel PDE1 Inhibitors with Anti-pulmonary Fibrosis EffectsJournal of Medicinal Chemistry, 2022
- Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunitiesPharmacology & Therapeutics, 2021
- Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosisActa Pharmaceutica Sinica B, 2021
- Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary FibrosisJournal of Medicinal Chemistry, 2020
- Role of cAMP and phosphodiesterase signaling in liver health and diseaseCellular Signalling, 2018
- Idiopathic pulmonary fibrosisThe Lancet, 2017
- Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidenceRespiratory Medicine, 2017
- Mechanisms of TGF-β Signaling from Cell Membrane to the NucleusCell, 2003